Onxeo S.A. announced that it will present new preclinical data confirming AsiDNA's abilities to protect from anticancer treatment toxicity and fight tumor resistance during poster and oral sessions at the upcoming American Association for Cancer Research Annual Meeting. The oral presentation will describe how AsiDNA™ efficiently prevented the emergence of resistances to tyrosine kinase inhibitors in several models of targetable oncogenic addiction and will point to the therapeutic opportunity of combining AsiDNA™ and TKI (tyrosine kinase inhibitors) to overcome resistance in a clinical setting. These data were obtained within the framework of the collaboration with Pr.

Gilles Favre. The poster presentation supports AsiDNA™'s potential to protect healthy cells from toxicities of several anti-cancer treatments. When combined with different anti-cancer treatments, AsiDNA induces its nuclear target engagement only in dividing cells, while preserving healthy non dividing cells.

In addition, in certain proliferating healthy cells, AsiDNA™ induces a stop in their division or boosts their DNA repair activity, thus protecting them from the toxic effects of anti-cancer treatments. These data were obtained in vivo and in vitro models within the framework of the collaboration with Pr. Marie Dutreix (Institut Curie).